Research Analysts Issue Forecasts for TNXP Q1 Earnings

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) – Investment analysts at Zacks Research issued their Q1 2026 EPS estimates for shares of Tonix Pharmaceuticals in a report issued on Monday, March 23rd. Zacks Research analyst D. Bautz anticipates that the company will earn ($3.14) per share for the quarter. The consensus estimate for Tonix Pharmaceuticals’ current full-year earnings is ($1,762.50) per share. Zacks Research also issued estimates for Tonix Pharmaceuticals’ Q2 2026 earnings at ($2.75) EPS, Q3 2026 earnings at ($2.48) EPS, Q4 2026 earnings at ($2.32) EPS, FY2026 earnings at ($10.52) EPS and FY2027 earnings at ($3.70) EPS.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Thursday, March 12th. The company reported ($3.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.16) by ($0.82). Tonix Pharmaceuticals had a negative net margin of 946.22% and a negative return on equity of 60.15%. The company had revenue of $5.39 million during the quarter, compared to analysts’ expectations of $2.97 million.

A number of other analysts also recently commented on TNXP. Weiss Ratings restated a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a report on Wednesday, January 21st. Wall Street Zen cut Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Tonix Pharmaceuticals currently has an average rating of “Hold”.

Tonix Pharmaceuticals Stock Down 6.3%

NASDAQ:TNXP opened at $12.88 on Thursday. The company has a market cap of $172.59 million, a P/E ratio of -0.90 and a beta of 1.88. The firm’s 50 day moving average is $15.42 and its two-hundred day moving average is $18.03. Tonix Pharmaceuticals has a fifty-two week low of $12.70 and a fifty-two week high of $69.97.

Hedge Funds Weigh In On Tonix Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in shares of Tonix Pharmaceuticals by 238.1% during the 3rd quarter. Vanguard Group Inc. now owns 556,957 shares of the company’s stock valued at $13,456,000 after acquiring an additional 392,225 shares in the last quarter. Balyasny Asset Management L.P. acquired a new stake in Tonix Pharmaceuticals in the 4th quarter valued at $2,895,000. Geode Capital Management LLC increased its holdings in Tonix Pharmaceuticals by 182.4% in the 2nd quarter. Geode Capital Management LLC now owns 175,212 shares of the company’s stock valued at $6,305,000 after purchasing an additional 113,175 shares in the last quarter. Nuveen LLC raised its position in Tonix Pharmaceuticals by 507.7% in the fourth quarter. Nuveen LLC now owns 93,402 shares of the company’s stock valued at $1,459,000 after purchasing an additional 78,033 shares during the period. Finally, Capital Fund Management S.A. acquired a new position in shares of Tonix Pharmaceuticals during the third quarter worth about $1,521,000. Hedge funds and other institutional investors own 82.26% of the company’s stock.

Insiders Place Their Bets

In other Tonix Pharmaceuticals news, CEO Seth Lederman purchased 15,000 shares of Tonix Pharmaceuticals stock in a transaction on Wednesday, March 18th. The shares were purchased at an average cost of $14.89 per share, with a total value of $223,350.00. Following the completion of the transaction, the chief executive officer directly owned 15,001 shares in the company, valued at approximately $223,364.89. This represents a 1,500,000.00% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.03% of the stock is currently owned by company insiders.

More Tonix Pharmaceuticals News

Here are the key news stories impacting Tonix Pharmaceuticals this week:

• Positive Sentiment: First participant dosed in a Phase 1 investigator‑initiated pharmacodynamic study of TNX‑1900 to assess potential for treating migraine and craniofacial pain; intranasal oxytocin blocks CGRP release in animal models and represents a mechanism distinct from current CGRP drugs, which could broaden Tonix’s pipeline if signals are positive. Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900
• Neutral Sentiment: Multiple outlets (Business Insider, Yahoo Finance, TipRanks) picked up the dosing announcement — that raises visibility and investor attention but the study is early‑stage (pharmacodynamic model), so clinical readouts and commercialization remain uncertain. Tonix Pharmaceuticals Announces First Participant Dosed (Business Insider)
• Negative Sentiment: Zacks Research substantially lowered its near‑term EPS forecasts for Tonix, cutting FY2026 and FY2027 estimates and issuing much larger expected losses per share (e.g., FY2026 now modeled at roughly -$10.52). Those revisions signal analyst concern about cash runway, development timelines and the likelihood of future dilution — a key reason for downward pressure on the stock. What is Zacks Research’s Estimate for TNXP FY2028 Earnings?

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.